http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Phthalocyanines as medicinal photosensitizers: Developments in the last five years
Li, Xingshu,Zheng, Bing-De,Peng, Xiao-Hui,Li, Song-Zi,Ying, Jia-Wen,Zhao, Yuanyuan,Huang, Jian-Dong,Yoon, Juyoung Elsevier 2019 Coordination Chemistry Reviews Vol.379 No.-
<P><B>Abstract</B></P> <P>Owing to their high extinction coefficients, long absorption wavelengths, and modification tunable photophysical and photochemical properties, phthalocyanines (Pcs) have been widely used as photosensitizers for photodynamic therapy (PDT). Advances made in the past five years on the development of Pcs as medicinal photosensitizers are reviewed and the main design considerations for medicinal applications of these substances are discussed.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Recent progresses made in the development of phthalocyanines for photodynamic therapy are outlined. </LI> <LI> Representative water-soluble phthalocyanines are presented. </LI> <LI> Main targeting strategies are discussed. </LI> <LI> Future challenges are also presented. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Li, Xingshu,Kim, C-yoon,Lee, Seunghyun,Lee, Dayoung,Chung, Hyung-Min,Kim, Gyoungmi,Heo, Si-Hyun,Kim, Chulhong,Hong, Ki-Sung,Yoon, Juyoung American Chemical Society 2017 JOURNAL OF THE AMERICAN CHEMICAL SOCIETY - Vol.139 No.31
<P>Switchable phototheranostic nanomaterials are of particular interest for specific biosensing, high-quality imaging, and targeted therapy in the field of precision nanomedicine. Here, we develop a 'one-for-all' nanomaterial that self-assembles from flexible and versatile phthalocyanine building blocks. The nanostructured phthalocyanine assemblies (NanoPcTBs) display intrinsically unique photothermal and photoacoustic properties. Fluorescence and reactive oxygen species generation can be triggered depending on a targeted, protein-induced, partial disassembly mechanism, which creates opportunities for low-background fluorescence imaging and activatable photodynamic therapy. In vitro evaluations indicate that NanoPcTB has a high selectivity for biotin receptor-positive cancer cells (e.g, A549) compared to biotin receptor-negative cells (e.g., WI38-VA13) and permits a combined photodynamic and photothermal therapeutic effect. Following systemic administration, the NanoPcTBs accumulate in A549 tumors of xenograft-bearing mice, and laser irradiation clearly Induces the inhibition of tumor growth.</P>
Albumin-binding photosensitizer capable of targeting glioma via the SPARC pathway
Xingshu Li,Jae Sang Oh,이윤지,Eun Chae Lee,Mengyao Yang,Nahyun Kwon,Tae Won Ha,Dong‑Yong Hong,Yena Song,Hyun Kyu Kim,Byung Hoo Song,최선,Man-Ryul Lee,윤주영 한국생체재료학회 2023 생체재료학회지 Vol.27 No.00
Background : Malignant glioma is among the most lethal and frequently occurring brain tumors, and the average survival period is 15 months. Existing chemotherapy has low tolerance and low blood-brain barrier (BBB) permeability; therefore, the required drug dose cannot be accurately delivered to the tumor site, resulting in an insufcient drug efect. Methods : Herein, we demonstrate a precision photodynamic tumor therapy using a photosensitizer (ZnPcS) capable of binding to albumin in situ, which can increase the permeability of the BBB and accurately target glioma. Albuminbinding ZnPcS was designed to pass through the BBB and bind to secreted protein acidic and rich in cysteine (SPARC), which is abundant in the glioma plasma membrane. Results : When the upper part of a mouse brain was irradiated using a laser (0.2 W cm−2) after transplantation of glioma and injection of ZnPcS, tumor growth was inhibited by approximately 83.6%, and the 50% survival rate of the treatment group increased by 14 days compared to the control group. In glioma with knockout SPARC, the amount of ZnPcS entering the glioma was reduced by 63.1%, indicating that it can target glioma through the SPARC pathway. Conclusion : This study showed that the use of albumin-binding photosensitizers is promising for the treatment of malignant gliomas.
Mesenchymal stem cell-driven activatable photosensitizers for precision photodynamic oncotherapy
Li, Xingshu,Kim, C-yoon,Shin, Jeong Min,Lee, Dayoung,Kim, Gyoungmi,Chung, Hyung-Min,Hong, Ki-Sung,Yoon, Juyoung Elsevier 2018 Biomaterials Vol.187 No.-
<P><B>Abstract</B></P> <P>Precise targeting with minimal side effects is of particular interest for personalized medicine, although it remains a challenge. Herein, we demonstrate precision photodynamic therapy (PDT) utilizing human mesenchymal stem cells (MSCs) as cellular vehicles to deliver a new activatable photosensitizer (PcS). <I>In vivo</I> real-time optical imaging tests indicated that PcS-loaded MSCs possess excellent tumor-homing properties. More importantly, dye transfer assays confirm that MSCs precisely transfer PcS into human colon cancer cells (HCT116) via the “bystander effect.” Upon localized light irradiation, the growth of intraperitoneal xenograft tumors was significantly inhibited by the photodynamic effect. These findings represent a promising strategy for precise oncotherapy.</P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Supramolecular photosensitizers rejuvenate photodynamic therapy
Li, Xingshu,Lee, Songyi,Yoon, Juyoung Royal Society of Chemistry, etc 2018 Chemical Society reviews Vol.47 No.4
<P>Owing to its spatiotemporal selectivity and noninvasive nature, photodynamic therapy (PDT) has become a clinically promising approach for the treatment of a wide range of cancers and other diseases. However, the full potential of PDT has not been achieved thus far as a consequence of the lack of optimal photosensitizers (PSs) and/or smart transport/activation strategies. These problems, which unfortunately lie at the core of the PDT paradigm, include the oxygen reliance limits, the effect of PDT on hypoxic tumors, limitations of light penetration, and undesired skin photosensitization induced by “always on” PSs. Recently, supramolecular approaches, which rely on the use of non-covalent interactions to construct biomedical active materials, have become suitable methods for developing innovative PSs. Non-covalent interactions enable supramolecular PSs to have sensitive and controllable photoactivities, important elements needed to maximize photodynamic effects and minimize side effects. In addition, versatile supramolecular PS-assemblies can be designed so that PDT occurs synergistically with other therapeutic modalities, <I>e.g.</I>, photothermal therapy, leading to a potential improvement of therapeutic effectiveness. In this review, recent progress made in the development of supramolecular PSs for rejuvenating PDT will be presented. Importantly, this discussion also provides a view of future advances that will likely be made in this area and their potential clinical applications.</P>
Li, Xingshu,Yu, Sungsook,Lee, Yoonji,Guo, Tian,Kwon, Nahyun,Lee, Dayoung,Yeom, Su Cheong,Cho, Yejin,Kim, Gyoungmi,Huang, Jian-Dong,Choi, Sun,Nam, Ki Taek,Yoon, Juyoung American Chemical Society 2019 JOURNAL OF THE AMERICAN CHEMICAL SOCIETY - Vol.141 No.3
<P>Albumin is a promising candidate as a biomarker for potential disease diagnostics and has been extensively used as a drug delivery carrier for decades. In these two directions, many albumin-detecting probes and exogenous albumin-based nanocomposite delivery systems have been developed. However, there are only a few cases demonstrating the specific interactions of exogenous probes with albumin <I>in vivo</I>, and nanocomposite delivery systems usually suffer from tedious fabrication processes and potential toxicity of the complexes. Herein, we demonstrate a facile “one-for-all” switchable nanotheranostic (NanoPcS) for both albumin detection and cancer treatment. In particular, the <I>in vivo</I> specific binding between albumin and PcS, arising from the disassembly of injected NanoPcS, is confirmed using an inducible transgenic mouse system. Fluorescence imaging and antitumor tests on different tumor models suggest that NanoPcS has superior tumor-targeting ability and the potential for time-modulated, activatable photodynamic therapy.</P> [FIG OMISSION]</BR>
Recent progress on photodynamic therapy and photothermal therapy
김희정,YANG MENGYAO,권나현,조문연,HAN JINGJING,Wang Rui,Qi Sujie,Li Haidong,Nguyen Van‐Nghia,Li Xingshu,Cheng Hong‐Bo,윤주영 대한화학회 2023 Bulletin of the Korean Chemical Society Vol.44 No.3
Noninvasive treatments for terminal cancer patients constitute a new trend in tumor treatment. Therefore, phototherapy, including photodynamic therapy (PDT) and photothermal therapy (PTT), has attracted considerable interest. Light and a photosensitizer (PS) are employed in both treatment methods. For PDT, the PS generates reactive oxygen species (ROS) when exposed to light, whereas for PTT, the PS generates heat. In this regard, the systematic design of new PSs has become an active area of phototherapy research in an effort to solve the problems associated with conventional PSs. In the past decade, acti- vatable and heavy-atom-free PSs have become significant research areas. Therefore, we discuss our recent contributions to the PDT and PTT in this account.